Skip to content

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1) - Hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027441
Enrollment
10
Registered
2017-05-23
Start date
2015-10-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable pancreatic cancer

Interventions

Sponsors

Osaka University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The case who was diagnosed histologically pancreatic cancer (2)The case who underwent R0 resection for pancreatic cancer.(3)The age is over 20 years old.(4)PS (ECOG) is 0 or 1. (5)Within 14 days before,major organ function is held by clinical examination.1)WBC is above 3,000 / mm3 and below 12,000/mm3. 2)Plt is above 100,000/mm3, 3)Hb is above 8.0g / dL, 4)AST (GOT) is below 100IU / L, and ALT (GPT)is below 100IU/L. 5)T-bil is below 2.0mg/dL. 6)Cr is below 1.2mg/dL 7)Ccr is above 50mL/min. (6)The patients can eat orally. (7)The patients who can start treatment within 4 to 12 weeks after surgery. (8)The patients who obtained the written consent before performing the various procedures for the test. Patients who can understand and are willing to sign the contents of the consent document.

Exclusion criteria

Exclusion criteria: (1)Patients who could not resected curatively.(2)Patients with active double cancer. (3)Patients with serious drug hypersensitivity or with a history of drug allergy.(4)Patients with serious complications.(5)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(6)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(7)Patients with active infection.(8)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast-feeding. Men who wish to become pregnant partner.(9)Patients with severe mental disorder.(10)Other patients whom the physician decided to be unsuitable for safely carrying out the present study.

Design outcomes

Primary

MeasureTime frame
safety

Secondary

MeasureTime frame
efficacy

Countries

Japan

Contacts

Public ContactHidetoshi Eguchi

Osaka University,Graduate School of Medicine Gastroenterological Surgery

heguchi@gesurg.med.osaka-u.ac.jp0668793251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026